HRT Financial’s BioXcel Therapeutics BTAI Stock Holding History

HRT Financial’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,062	Closed	-$28K	–	3842
2025 Q4	$28K	Buy	+18,062	New	+$37.3K	﹤0.01%	2947
2025 Q1	–	Sell	-1,594	Closed	-$9K	–	2571
2024 Q4	$9K	Buy	+1,594	New	+$13.3K	﹤0.01%	2290
2024 Q3	–	Sell	-3,313	Closed	-$67K	–	2458
2024 Q2	$67K	Buy	+3,313	New	+$111K	﹤0.01%	1803
2023 Q4	–	Sell	-4,519	Closed	-$182K	–	2352
2023 Q3	$182K	Buy	+4,519	New	+$457K	﹤0.01%	1855
2022 Q3	–	Sell	-2,519	Closed	-$531K	–	2831
2022 Q2	$531K	Buy	+2,519	New	+$530K	0.01%	1430
2021 Q3	–	Sell	-3,321	Closed	-$1.54M	–	3303
2021 Q2	$1.54M	Buy	3,321 +2,774	+507%	+$1.51M	0.01%	759
2021 Q1	$377K	Buy	+547	New	+$440K	﹤0.01%	1979

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HRT Financial's BTAI Position: Q1 2026 in Review

HRT Financial sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 18,062 shares — an estimated $28K sold.

HRT Financial first reported a position in BTAI in Q1 2021 and held it in 7 quarters. The position peaked at $1.54M in Q2 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

HRT Financial reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 18,062 BioXcel Therapeutics shares in Q1 2026, an estimated $28K.
HRT Financial first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 7 quarters.
HRT Financial's BioXcel Therapeutics position peaked at $1.54M in Q2 2021.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.